ArticleCureus2025
Minoxidil Overdose: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Life-threatening toxicity after the ingestion of a topical minoxidil solution: a case report.Journal of medical case reports · 2026Article
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minoxidil is a potent vasodilator originally used to treat severe refractory hypertension. Hypertrichosis is a common side effect of minoxidil, which led to the development and marketing of topical preparations for treating androgenetic alopecia (AGA). Minoxidil is primarily used to treat AGA; however, its inappropriate use can cause systemic side effects. Herein, we present the case of a 61-year-old Japanese man with an overdose of oral minoxidil that led to hypotension, breathlessness, edema, weight gain, and facial flushing. As the vital signs and results of laboratory and imaging tests were generally normal, no treatment was initiated. Two weeks after the initial visit, the patient's body weight decreased by approximately 10 kg, and the edema disappeared. To date, 14 patients have been reported to have developed systemic side effects following an overdose of minoxidil-containing medications. Our literature review identified that systemic symptoms related to minoxidil overdose occurred in 10 of 14 patients after ingestion of a topical formulation, three after tablet ingestion, and one after application of a large amount of topical solution to the scalp. All 14 patients experienced hypotension and/or tachycardia. These symptoms occurred within six hours of the ingestion of 100-3000 mg minoxidil. One of 14 patients presented with a complication of myocardial infarction, and no patient died. Interestingly, fluid therapy was ineffective in the treatment of hypotension related to minoxidil overdoses. Since the primary pathophysiological effect of minoxidil is a decrease in systemic vascular resistance by arteriolar vasodilation, peripherally acting alpha-adrenergic agonists, such as phenylephrine, midodrine, and norepinephrine, may be safer and more effective than dopamine and epinephrine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.